Drakenterprises

Not clinical advice. Clinical Evidence is a current-awareness feed. It is not a clinical decision-support system, not medical advice, and not a substitute for clinical judgment, institutional protocols, or the original sources. Full text, NCCN recommendations, and Cochrane review bodies are not reproduced here.

All trials

TrialNCT07804498

CITADEL: Effectiveness of CITicoline in Preventing Cognitive Decline After DELirium

Status
RECRUITING
Phase
PHASE2
Last update posted
09/04/2026
Start
06/03/2026
Sponsor
University of Milano Bicocca
Specialties
orthopaedics

Conditions: Perioperative Delirium; Hip Fracture; Post-Operative Cognitive Decline in Older Adults

Brief summary

The aim of this study is to assess whether citicoline (TRAUSAN), a neuroprotective agent involved in membrane phospholipid synthesis and neurotransmission, can prevent or attenuate cognitive decline in older adults who develop perioperative delirium during hospitalization for proximal hip fracture. Delirium is a frequent and severe complication in this population and is associated with cognitive and functional deterioration, institutionalization, and mortality. Participants will be randomly assigned (1:1) to receive citicoline 1000 mg/day for 6 months after discharge, or usual care. Cognitive and functional status will be evaluated at discharge and subsequently at 3 and 6 months follow-up visits.

Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.

Clinical Evidence